, Tracking Stock Market Picks
Enter Symbol:
Rating: CRL

Charles River Laboratories International, Inc. (NYSE: CRL) upgraded to Outperform by Wells Fargo

Thursday,  Jan 7, 2016  10:25 AM ET by Lynn Gilbert

Wells Fargo upgraded Charles River Laboratories International, Inc. (NYSE: CRL) to Outperform.
Previously, Wells Fargo rated Charles River Laboratories International, Inc. (NYSE: CRL) to Market Perform on 03/27/2013, when the stock price was valued at $44.11.

Charles River Laboratories International, Inc. (Charles River) is a global provider of solutions that advance the drug discovery and development process, including research models and associated services, and outsourced preclinical services. The Company operates in two segments: Research Models and Services (RMS) and Preclinical Services (PCS). The Company provides the animal research models required in research and development of drugs, devices and therapies. Charles River?s customer base includes global pharmaceutical companies, a range of biotechnology companies, as well as government agencies, hospitals and academic institutions worldwide. The Company operates approximately 70 facilities in 17 countries worldwide. During the fiscal year ended December 27, 2008 (fiscal 2008), the Company acquired NewLab BioQuality AG and MIR Preclinical Services.

The investment research content is provided by Wells Capital Management, a registered investment adviser and wholly owned subsidiary of Wells Fargo Bank, N.A. Our economists’ expertise on domestic markets, and national and global trends, is an important resource to the firm. Wells Capital Management economists are known for their thoughts on investment strategy, macro-economic forecasts and other top-down analysis, and share their views on bonds, midcaps and liquidity management in their publications.

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy